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Abstract
Restrictive dermopathy (RD) is a rare and extremely severe congenital
genodermatosis, characterized by a tight rigid skin with erosions at flexure
sites, multiple joint contractures, low bone density and pulmonary insufficiency
generally leading to death in the perinatal period. RD is caused in most patients
by compound heterozygous or homozygous ZMPSTE24 null mutations. This
gene encodes a metalloprotease specifically involved in lamin A post-translational
processing. Here, we report a total of 16 families for whom diagnosis and
molecular defects were clearly established. Among them, we report seven new
ZMPSTE24 mutations, identified in classical RD or Mandibulo-acral dysplasia
(MAD) affected patients. We also report nine families with one or two affected
children carrying the common, homozygous thymine insertion in exon 9 and
demonstrate the lack of a founder effect. In addition, we describe several new
ZMPSTE24 variants identified in unaffected controls or in patients affected wit...
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New ZMPSTE24 (FACE1) mutations in patients
affected with restrictive dermopathy or related
progeroid syndromes and mutation update
Claire Laure Navarro*,1,2, Vera Esteves-Vieira3, Se´bastien Courrier1,2, Amandine Boyer3,
Thuy Duong Nguyen4,5, Le Thi Thanh Huong4,6, Peter Meinke4,14, Winnie Schro¨der4, Vale´rie Cormier-Daire7,
Yves Sznajer8, David J Amor9, Kristina Lagerstedt10, Martine Biervliet11, Peter C van den Akker12,
Pierre Cau1,2,13, Patrice Roll1,2,13, Nicolas Le´vy1,2,3, Catherine Badens1,2,3, Manfred Wehnert4,15 and
Annachiara De Sandre-Giovannoli1,2,3
Restrictive dermopathy (RD) is a rare and extremely severe congenital genodermatosis, characterized by a tight rigid skin with
erosions at flexure sites, multiple joint contractures, low bone density and pulmonary insufficiency generally leading to death
in the perinatal period. RD is caused in most patients by compound heterozygous or homozygous ZMPSTE24 null mutations.
This gene encodes a metalloprotease specifically involved in lamin A post-translational processing. Here, we report a total
of 16 families for whom diagnosis and molecular defects were clearly established. Among them, we report seven new
ZMPSTE24 mutations, identified in classical RD or Mandibulo-acral dysplasia (MAD) affected patients. We also report nine
families with one or two affected children carrying the common, homozygous thymine insertion in exon 9 and demonstrate the
lack of a founder effect. In addition, we describe several new ZMPSTE24 variants identified in unaffected controls or in
patients affected with non-classical progeroid syndromes. In addition, this mutation update includes a comprehensive search
of the literature on previously described ZMPSTE24 mutations and associated phenotypes. Our comprehensive analysis of the
molecular pathology supported the general rule: complete loss-of-function of ZMPSTE24 leads to RD, whereas other less severe
phenotypes are associated with at least one haploinsufficient allele.
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INTRODUCTION
Restrictive dermopathy (RD, OMIM #275210) is a rare and extremely
severe congenital genodermatosis, lethal in the perinatal period. The
first signs include intrauterine growth retardation and fetal hypo-
kinesia deformation sequence. At birth, a rigid and tight skin with
erosions at flexure sites is noted together with epidermal hyper-
keratosis, a microstomia with a peculiar shape in an open ‘O’
position, a small pinched nose, microretrognathism, sparse or absent
eyelashes and eyebrows. Typical orthopedic features are bone miner-
alization defects, thin dysplastic clavicles and generalized arthrogry-
posis, which usually lead to a characteristic phenotype. Early neonatal
death is usually due to severe pulmonary insufficiency.1,2 In the
original study, we were able to identify that this early lethal disorder is
caused by lamin A-specific defects either due to dominant LMNA
mutations or, in most cases, to recessive ZMPSTE24 null
mutations.1,3 Lamins are ubiquitous nuclear proteins constituting
the type V intermediate filaments subfamily; they are subdivided in
A- and B-type lamins, respectively encoded by the LMNA, LMNB1
or LMNB2 genes (OMIM reference #: 150330, 150340, 150341).4,5
Lamins are major components of the nuclear lamina, a filamentous
meshwork underlying the inner nuclear membrane involved in
nuclear shape, nuclear pore complex spacing and resistance to
mechanical stress. Moreover, by their numerous interactions and
nucleoplasmic localization in the nuclear matrix, lamins have been
involved in many other major nuclear functions, including
regulation of gene expression, chromatin organization and
DNA replication and repair (for review, see Broers et al6 and
Prokocimer et al7).
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Lamins A and C are the major isoforms expressed by the LMNA
gene through alternative splicing. Although lamin C is directly
translated as a mature isoform from mRNAs, lamin A is first
synthesized as a precursor called prelamin A, which undergoes four
post-translational processing steps.8,9 These include: farnesylation of a
Cys residue localized in a C-terminal ‘CaaX’ farnesylation motif
(CSIM amino acids); proteolytic cleavage removing the SIM
tripeptide, methylation of the C-terminal farnesylated Cystein
residue and finally, a last proteolytic cleavage removing the
C-terminal 15 amino acids, performed by the zinc metalloprotease
STE24 (ZMPSTE24), generating a non-farnesylated mature lamin A.
LMNA mutations are known to cause Hutchinson–Gilford progeria
syndrome (HGPS, OMIM #176670), because of the accumulation of
an unprocessed lamin A deleted precursor. Clinically, HGPS is
characterized by segmental features of premature aging including
alopecia, loss of subcutaneous fat and early death (usually in the
second decade), mostly due to myocardial infarction.10 After the
identification of the main genetic cause of HGPS as a de novo LMNA
mutation (c.1824C4T, Gly608Gly) affecting splicing and prelamin A
maturation,11,12 mutations in ZMPSTE24 were then identified in
patients affected by severe Mandibulo-acral dysplasia associated with
B-type lipodystrophy (MAD-B),13 and later in RD.1,3,14 Clinically,
MAD is characterized by skeletal abnormalities including hypoplasia
of the mandible and clavicles, acro-osteolysis of distal phalanges,
cutaneous atrophy and lipodystrophy. MAD-A, linked to LMNA
mutations, is associated with a partial lipodystrophy of the
extremities. On the opposite, in typical MAD-B, lipodystrophy is
generalized, an earlier age of onset is observed (often during the first
year of life) and the median age of death is 30 years. Other mutations
were found in additional cases of RD15–21 and progeroid syndromes
phenotypically overlapping with MAD and HGPS that can be
nosologically classified as MAD-B, given the common molecular
basis, involving ZMPSTE24 deficiency.13,22–28 RD, MAD-B and HGPS
share a common pathophysiological mechanism based on the
abnormal accumulation of a wild type or modified lamin A
precursors.
Here, we report the results obtained in 19 families referred for
molecular diagnosis to our genetic laboratories on the basis of RD or
MAD phenotypes. Among them, we identified five new compound
heterozygous mutations in ZMPSTE24 and two novel homozygous
mutations. In three unrelated cases clinically diagnosed as RD at birth,
no mutation was observed in either ZMPSTE24 or LMNA. In
addition, in order to determine whether the common c.1085dupT
mutation was associated with a founder haplotype, we explored six
intragenic ZMPSTE24 SNPs in homozygous patients and their
heterozygous parents. Bioinformatic approaches regarding the muta-
tions’ impact at the RNA and protein levels are described as useful
tools to predict the pathogenicity of new mutations. Finally, based on
a complete review of the literature and the novel patients reported
here, the physiopathology of premature aging syndromes linked to
ZMPSTE24 mutations is discussed, as well as clinical and molecular
diagnostic implications.
MATERIALS AND METHODS
Informed consent and DNA/RNA extractions
Informed consent for genetic testing was obtained from the parents of all the
patients included in this study, complying with the ethical guidelines of the
institutions involved. Genomic DNA was extracted from peripheral blood
lymphocytes by standard procedures. RNA was obtained either from lympho-
blastoid or fibroblast cell lines. Lymphoblastoid cell lines were established from
patients’ or their parents’ lymphocytes by EBV standard immortalization
procedures. Fibroblasts were obtained from skin biopsies and cultured in a
DMEM medium containing 10% fetal calf serum, 2mm/ml L-glutamine and
100U/ml penicillin–streptomycin (Invitrogen-Life Technologies, Carlsbad, CA,
USA). RNA extraction was performed using TRIzol following the manufa-
cturer’s recommendations (Invitrogen-Life Technologies).
Genomic and transcriptional analysis
Reverse transcription was performed using a Superscript II reverse transcrip-
tase (Invitrogen-Life Technologies) following the manufacturer’s recommenda-
tions. ZMPSTE24 mRNA sequence reference is RefSeq NM_005857.4 and the
following RT-PCR primers, used to indicate the splicing defect in the patient
from family 6, were located in exon 6: 50-TGCCTGAGGGAAAGCTTAAA-30
(forward) and in exon 9: 50-CCAATAAGAGTGGGTTGGCTA-30 (reverse).
All the other primers were previously described in Navarro et al.1 The
sequencing reactions were performed with a dye terminator procedure, and
loaded on a capillary automatic sequencer CEQ 8000 (Beckman Coulter, Brea,
CA, USA) according to the manufacturer’s recommendations. They were
controlled using a different dye terminator procedure and loaded onto an ABI
3130XL automatic sequencer (Applied Biosystems-Life Technologies, Carlsbad,
CA, USA). All sequence variations are described according to the Human
Genomic Variation Society recommendations available at http://www.hgvs.org/
mutnomen and the nomenclature of each mutation was checked using the
Mutalyzer software http://www.lovd.nl/mutalyzer/.
SNP primers amplification and PCR annealing temperatures
NCBI references for the amplified SNPs were rs7514099, rs7516571, rs6600323,
rs10489430, rs1015354, rs6664294, respectively. The sequences of the primers
used are shown in Supplementary Table S1. In all, 50ml of the PCR reaction
mixture contained 5ml of buffer 10X, 2ml MgCl2 (50mM), 0.5ml dNTP
(25mM), 5 pmoles of each primer (forward and reverse), Taq Polymerase 1U,
50ng of genomic DNA. The volume was completed to 50ml with sterile water.
All PCR reagents were from Invitrogen-Life Technologies. Cycling conditions
were a 3-min initial denaturation step at 94 1C, followed by 35 cycles of: 30 s at
94 1C, 30 s at 61 1C, 30 s at 72 1C and a last final 3-min elongation step at 72 1C.
To amplify exon 9, a proof reading (high fidelity) Pfu polymerase (Fermentas,
Villebon sur Yvette, France) was used.
Bioinformatic tools
All web sites and databases addresses used in the manuscript are detailed in
Supplementary Table S2.
RESULTS
Molecular findings
The genomic analysis of the entire ZMPSTE24/FACE1 coding
sequence and intronic boundaries, allowed the identification of
causative mutations in 16 of 19 families with one or two affected
children, referred to the laboratories for molecular diagnosis of RD or
Mandibulo-acral phenotypes, based on clinical and, in some cases,
histopathological evaluation.
Two deletions, one of them novel, were observed in two different
families (Figure 1 and Table 1). In family 1 (Figure 1Aa), the index
case presented an adenine deletion located in exon 1, c.50delA
(previously described in Smigiel et al20), in a compound
heterozygous state with the common c.1085dupT duplication. In
family 2 (Figure 1Ab), the child of a consanguineous Turkish couple,
presented a novel homozygous deletion of two nucleotides in exon 2,
c.209_210delAT. In a third family (Figure 1Ac), the compound
heterozygous mutations c.54dupT, previously described in Moulson
et al14 and a novel nonsense mutation located in exon 7 (c.826C4T)
were observed. A further novel homozygous mutation, c.1105C4T
located in exon 9, causing a stop gain, led to RD in a consanguineous
German family 4 (Figure 1Ad). All the frame shift mutations resulted
in premature termination codons. The predicted effects on translation
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are p.Lys17Serfs*21, p.Tyr70Serfs*4, p.Ile19Tyrfs*28, p.Arg276* and
p.Arg369*, respectively (Table 1).
We also identified four novel splice site mutations in three families
(Figure 1B; Table 2). Regarding family 5, we only received DNA from
both parents, as biological samples from the affected child were not
available. In view of a presumed prenatal diagnosis, the analysis was
performed in search of heterozygous pathogenic mutations, inferring
their transmission to the affected child. Indeed, we observed two
Figure 1 Segregation of ZMPSTE24 mutations leading to RD. (A) Segregation of novel ZMPSTE24 frame-shift mutations leading to RD. The pedigrees show
women as circles, men as rectangles, affected children as black-filled symbols and prenatally diagnosed fetuses as rhomboid symbols. ZMPSTE24
mutations are shown right to the pedigrees. The critical mutant regions in the sequences are underlined in yellow. (a) The affected child of a Dutch family
carried a heterozygous adenine deletion in exon 1 (c.50delA) with the common thymidine duplication located in exon 9 (c.1085dupT). Sequence
pherograms of exon 1 (forward direction) show a frame-shift. (b) The affected child of a consanguineous Turkish family carried a homozygous deletion of
two base pairs in exon 2, c.209_210AT. (c) The affected child of a Swedish family was compound heterozygous for a c.826C4T transition and the
previously reported c.54dupT duplication. (d) In a consanguineous German family, the novel homozygous transition c.1105C4T resulted in RD.
(B) Segregation of splice site mutations in two RD families. (a) Genomic splice site mutations identified in both parents of a RD fetus in family 5 (NA,
tissue samples not available). (b) Genomic splice site mutation found in the genomic DNA of the index cases’ father in family 6. (c) Left panel: RT-PCR
products amplified from cDNAs of the father and control samples separated by agarose gel electrophoresis. Lane 1: molecular size ladder; Lane 2: RT-PCR
father; Lane 3: RT-PCR positive control; Lane 4: negative control. Besides the expected 475-bp amplicon, an additional shorter amplicon of 290-bp was
found in lane 2 as indicated by an asterisk. Right panel: sequencing pherogram of the 290-bp amplicon showing exon 7 skipping.
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Table 1 Summary of patients affected with progeroid syndromes carrying pathogenic ZMPSTE24 mutations
Patients Mutations (allele 1; allele 2) Position Protein prediction Protein function
Prelamin A
accumulation Reference
Restrictive dermopathy
RD—family 1 c.50delA; c.1085dupT Exon1; exon 9 p.Lys17Serfs*21/
p.Leu362Phefs*19
NA NA Present report and
Smigiel et al20
RD—family 2 (consanguineous Turkish) c.209_210delAT;
c.209_210delAT
Exon 2 p.Tyr70Serfs*4 NA NA Present report
RD—family 3 c.54dupT; c.826 C4T Exon 1; exon 7 p.Ile19Tyrfs*28/p.Arg276* NA NA Present report and
Moulson et al14
RD—family 4 (consanguineous German) c.1105C4T; c.1105C4T Exon 9 p.Arg369* NA NA Present report
RD—family 5 c.475-2A4G; c.628-2A4G Intron 4; intron 5 p.Thr159_Leu209del/
p.Val210Aspfs*21
NA NA Present report
RD—family 6 c.954þ2 T4A; c.1085dupT Intron 7; exon 9 p.Gly256Glufs*2/
p.Leu362Phefs*19
NA NA Present report
Nine additional RD—families c.1085dupT; c.1085dupT Exon 9 p.Leu362fs*19 NA NA Present report
Patient P2 c.1085dupT; c.1085dupT Exon 9 p.Leu362PhefsX19 Null Complete Navarro et al3
(patient P2)
Patient P3 c.1085dupT; r.271_627del Exon 9; exon 3-5del p.Leu362Phefs*19/
p.Leu91_Leu209del
Null Complete Navarro et al3 (P3)
Patient P5 c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 Null Complete Navarro et al3 (P5)
Patient P6 c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 Null Complete Navarro et al3 (P6)
Patient P7 c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 Null Complete Navarro et al3 (P7)
Patient P8 c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Navarro et al3 (P8)
Patient P9 c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Navarro et al3 (P9)
Patient P10 c.1085dupT; c.1249C4T Exon 9; exon 10 p.Leu362Phefs*19/p.Gln417* NA NA Navarro et al3
(P10)
Patient P11 c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Navarro et al3
(P11)
Patient P12 c.1085dupT; c.295delC Exon 9 p.Leu362Phefs*19/
p.Pro99Leufs*38
NA NA Navarro et al3
(P12)
Consanguineous Dutch family c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Moulson et al14
American family c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 Null Complete Moulson et al14
Consanguineous Guatemalan family c.591dupT; c.591dupT Exon 5 p.Ile198fs*19 Null Complete Moulson et al14
Mennonite kindred c.54dupT; c.54dupT Exon 1 p.Ile19Tyrfs*28 NA NA Moulson et al14
Isolated Dutch case c.1085dupT; c.591dupT Exon 9 p.Leu362Phefs*19/
p.Ile198fs*19
NA NA Moulson et al14
Case report—Iranian patient c.627 þ1G4C; c.627 þ1G4C Intron 5 p.Thr159_Leu209del Null Presence Sander et al16
Case report c.1385C4T;? Exon 10 p.Leu462Arg/? NA NA Thill et al17
Chinese patient c.715G4T; c.715G4T Exon 6 p.Glu239* NA NA Chen et al15
Case report 1 c.691G4T; c.691G4T; Exon 6 p.Glu231* NA NA Jagadeesh et al19
Case report 2 c.691G4T; c.691G4T; Exon 6 p.Glu231* NA NA Jagadeesh et al19
Case report Iranian c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Kariminejad et al44
Caucasian case report c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Morais et al45
Case report Mennonite Kindred c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Li et al46
RD-600 c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Ahmad et al18,23
RD-500—consanguineous Mexican family c.1020G4A; c.1020G4A Exon 8 p.Trp340* NA NA Ahmad et al18,23
Two affected sibling c.50delA; c.584_585delAT Exon1; exon 5 p.Lys17Serfs*21/
p.Tyr195Phefs*22
NA NA Smigiel et al20
Case report Turkish c.1085dupT; c.1085dupT Exon 9 p.Leu362Phefs*19 NA NA Yesil et al47
Two sibling c.715G4T; c.715G4T Exon 6 p.Glu239* NA NA Lu et al21
Mandibuloacral dyslplasia (MAD-type B) and other progeroı¨de syndromes
MAD-B—Family 7 (Turkish) c.1204-1G4A; c.794A4G Intron 9; exon 7 p.Val402Phefs*6; p.Asn265Ser present report
MAD-B (MAD600) c.1085dupT; c.1018T4C Exon 9; exon 8 p.Leu362Phefs*19/
p.Trp340Arg
Null/residual
activity
NA Agarwal et al13
HGPS/MAD c.1085dupT; c.794A4G Exon 9; exon 7 p.Leu362Phefs*19/
p.Asn265Ser
Null/residual
activity
Partial Shackleton et al28
Australian HGPS/MAD c.1085dupT; c.794A4G Exon 9; exon 7 p.Leu362Phefs*19/
p.Asn265Ser
NA NA Agarwal et al22
HGPS/MAD c.1204_1225del22;
c.1204_1225del22a
Exon 10 p.Val402Serfs*1 Null Complete b Denecke et al26
Severe MAD—two affected sister c.121C4T; c.743C4T Exon 1; Exon 6 p.Gln41*/p.Pro248Leu Null/residual
activity
Partial Miyoshi et al27
Early onset MAD—(MAD4700) c.743C4T; c.1349G4A Exon 6; exon 10 p.Pro248Leu/p.Trp450* NA NA Ahmad et al18,23
MAD—with severe skeletal phenotype c.794A4G; c.207_208delCT Exon 7; exon 2 p.Asn256Ser/p.Tyr70Serfs*4 NA NA Cunningham
et al25
MAD-B with muscular defects—case
report
c.281T4C; c.281T4C Exon 3 Leu94Pro/Leu94Pro Residual Partial Ben Yaou et al24
Abbreviation: NA, non available.
Patients previously described and reported here (shown in italic) and their associated mutations are detailed and resumed according to their phenotypic features.
aZMPSTE24 mutations associated with a heterozygous LMNA mutation, p.R654*.
bOne part of the (pre)lamin A pool, is not farnesylated because of the presence of the p.R654* mutation.
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heterozygous novel splice site mutations, each carried by one parent:
one at the acceptor splice site of intron 4 (c.475-2A4G) in the father,
the other at the acceptor splice site of intron 5 (c.628-2A4G) in the
mother (Figure 1Ba and Table 1). We could not derive cell lines from
the parents, in order to experimentally investigate on the pathogenic
effect of these mutations at the transcript level. Nevertheless, as both
mutations directly affect acceptor splice sites, they are predicted to be
dramatically deleterious.
In family 6, one mutation affecting the exon 7 donor splice site
(c.954þ 2T4A) was inherited from the father whereas the common
mutation c.1085dupTwas inherited from the mother (Figure 1Bb and
Table 1). The father’s transcriptional exploration by RT-PCR, using a
forward primer in exon 6 and a reverse in exon 9, showed a shorter
amplicon of about 290 bp (Figure 1Bc), compared with the normal
amplicon of 475 bp. The shorter PCR product was gel-extracted
and sequenced, showing a complete deletion of exon 7 (Figure 1Bd).
This deletion is predicted to cause a frame shift leading to a
premature termination codon (p.Gly256Glufs*2).
The index case of family 7 showed a severe clinical phenotype of
Mandibulo-acral dysplasia (MAD) with onset before age 2. Muta-
tional analysis in ZMPSTE24 revealed the compound heterozygous
mutations c.1204-1G4A and c.794A4G in a Turkish family
(Figure 2). Although the novel splice site mutation c.1204-1G4A
leads to a predicted truncated ZMPSTE24 p.Val402Phefs*6, the
previously described missense transversion c.794A4G results in a
mutant ZMPSTE24 p.Asn265Ser classifying the affected siblings in
family 7 as MAD-B.25
Nine additional families with one or more affected children were
also investigated: each index patient carried the homozygous common
null c.1085dupT mutation (data not shown, Table 1). This mutation
was previously identified as the most frequent one involved in RD.3,14
Based on molecular genetics findings, seven families asked for
prenatal diagnosis of RD after genetic counseling. As a result, two
homozygous wild type, six heterozygous and two homozygous or
compound heterozygous RD fetuses were identified.
In three patients diagnosed as being affected with RD, no
potentially pathogenic sequence variation was observed in the coding
regions and intronic boundaries of the ZMPSTE24 and LMNA genes.
However, clinical or histopathological findings in the children turned
out to present several but not all features of typical RD (ie, atresia,
total absence of dermis, abdominal inflammatory processes, advanced
bone age or atypical dysmorphic features). Thus, the patients were
probably affected with clinically similar forms of congenital arthro-
gryposis because of other molecular genetic defects.
In a larger general screening of patients affected with progeroid
syndromes other than classical RD, we identified three new and most
likely non-pathogenic heterozygous ZMPSTE24 variants. The hetero-
zygous c.990C4T (p.Leu330Leu) in exon 8 was only identified in the
healthy father of a child affected with a De Barsy-like syndrome
(OMIM #219150), who subsequently died due to a concurrent
Table 2 Splice site calculations using HSF, BDGP and NetGene2 for
splice site mutations found in the present study
DNA variationa Amino-acid exchange
HSFb NetGene2c BDGPd
Wt Mut Wt Mut Wt Mut
c.475-2A4G p.Thr159_Leu209del 93.01 — 0.83 — 0.99 —
c.627þ1G4C p.Thr159_Leu209del 94.09 67.26 0.47 — 0.98 —
c.628-2A4G p. Val210Aspfse21 95.05 66.11 0.92 — 0.95 —
c.954þ2 T4A p. Gly257Glufse2 87.31 — 0.91 — 0.98 —
c.1204-1G4A p. Val402Phefse6 96.47 67.53e 0.77 — 0.99 —f
aTranscript reference: NM_005857.4.
bhttp://www.umd.be/HSF/.
chttp://www.cbs.dtu.dk/services/NetGene2/.
dhttp://www.fruitfly.org/seq_tools/splice.html.
eNew splice site considered with 83.93.
fNew splice site considered with 0.9.
Figure 2 ZMPSTE24 compound heterozygous mutations c.794A4G and c.1204-1G4A leading to MAD-B in a Turkish family. Segregation of the mutations
ZMPSTE24 c.794A4G and c.1204-1G4A in family 7 and sequencing pherograms of ZMPSTE24 c.794A4G and c.1204-1G4A in the index case.
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infection, whereas both the child and the healthy mother carried a
heterozygous c.770-131C4T variant in intron 6. Both are rare
polymorphic variants with a frequency of 0.4% and 1.2% respectively,
in a healthy reference population (rs116284141, rs78985808,
http://browser.1000genomes.org/index.html). No second potentially
pathogenic variant was observed for this patient in the coding regions
and intronic boundaries of both ZMPSTE24 and LMNA genes.
Furthermore, mutations in PYCR1 have been subsequently identified
as described in De Barsy syndrome.29,30 In addition, no prelamin A
was detected by western blot in the patient’s skin fibroblasts. In all,
60% of his fibroblasts’ nuclei showed morphological abnormalities,
including large aggregates or misdistribution of lamin A/C. However,
no blebs or herniations lacking lamin B, which are usually observed in
ZMPSTE24-deficient cells, were found.1,3,14,31 The nuclear
abnormalities observed in this patient could be due to mutations of
lamin A partners or other nuclear proteins. Another child of a
consanguineous couple was affected with a complex progeroid
phenotype, including neonatal insulin resistance, lipodystrophy,
facial dysmorphism as well as growth and psychomotor retardation.
The c.1035A4G (p.Thr345Thr) and c.1356C4G (p.Phe452Leu)
heterozygous variants were observed in exons 8 and 10 of the
ZMPSTE24 gene, respectively. Both had been transmitted, in cis,
from the healthy mother, excluding them as being causative per se of
the phenotype. In addition, the child carried these variants in
association with a de novo LMNA variant in exon 2 (c.438C4T;
p. Ala146Ala). The human splicing factor (HSF) calculation tool
predicted a SF2/ASF site to be broken by this mutation, which could
be associated with a frame-shift exon 2 skipping. Nonetheless, this
variant has been found with a frequency of 3% in a healthy reference
population (rs80356805, http://browser.1000genomes.org/index.html)
and no shorter lamin A isoform nor reduced levels of lamin A/C were
found in western blot analyses in the child’s fibroblasts. Instead, a
slight prelamin A accumulation was observed (data not shown).
Given the latter observation, we assume that the digenic-3 variants
combination probably concur to determine part of the child’s
features, that is, lipodystrophy and insulin resistance. Nonetheless,
the phenotypic features of the patient are not typical of a ZMPSTE24-
related progeroid syndrome and additional genetic or environmental
factors must be involved in the determination of the phenotype. In
particular, this patient is affected with psychomotor retardation,
which has never been reported in lamin A-linked progeroid
syndromes, and is issued from a consanguineous union, suggesting
the probable occurrence of identical-by-descent homozygous
mutations in one or more genomic loci that would concur to
determine her complex phenotype.
Is there a founder effect of the common c.1085dupT mutation?
In order to check whether the common mutation c.1085dupT is
associated with a common founder haplotype, we explored the
haplotypes of all the family members carrying at least one c.1085dupT
allele. Haplotypes were built on six intragenic SNPs reported in the
NCBI database (http://www.ncbi.nlm.nih.gov/snp). We analyzed 15
families with one or two affected children carrying the c.1085dupT
mutation. All the patients were either described by our team in
previous publications,1,3 or reported in this study. All individuals
studied were Caucasians although they had different geographic
origins. Several haplotypes were found to be associated with the
c.1085dupT insertion (data not shown), indicating absence of a
founder effect and suggesting independent events of a sporadic
de novo elongation of a T stretch in a region of microsatellite
instability.32 However, an ancestral haplotype was recently
found for this mutation in an old colony of Mennonites and
Hutterites.33
DISCUSSION
Diagnostic strategies
As concluded by previous studies and confirmed by the cases
reported here, the classic RD phenotype is linked to ZMPSTE24
null mutations whereas LMNA can be mutated in some less severe
dominant RD-like phenotypes, which can overlap with severe
neonatal HGPS forms. Thus, in classical RD phenotypes, whose
clinical features are very typical and recognizable, physicians
should be prompted to first screen the ZMPSTE24 gene in the
context of genetic counseling. Exon 9, which harbors the major
mutation, should be explored first, associating direct sequencing
(for the PCR of exon 9, a polymerase with proof reading activity
should be used) and fragment length analysis, because of the
difficulties linked to the study of this region,3 followed by the
complete screening of the gene if the most common mutation has
not found. As a second step, LMNA should be screened, based on
the existence of some extremely severe lamin-associated progeroid
syndromes that could be clinically diagnosed at birth as RDs. This
was the case regarding a patient initially characterized as RD
carrying a LMNA splice mutation (c.1968þ 1G4A) reported in
previous studies.1,34 Thus, initial clinical expertise is crucial to
direct the appropriate mutational analysis. In this study, all
patients referred to our laboratory for ZMPSTE24 screening in
whom no mutation was detected, were proven not to be affected
with classical RD after subsequent clinical investigation.
In our first publication associating RD to ZMPSTE24 mutations
published in 2004, we reported a patient carrying the heterozygous
c.1085dupT mutation.1 However, we later discovered that the patient
was homozygous for that mutation as corrected by us and confirmed
in other patients.3 We take advantage of this publication to
definitively clarify this point; indeed the original erroneous data are
still sometimes discussed in the literature. We thus wish to highlight
the fact that all classical RD patients carry homozygous or compound
heterozygous null ZMPSTE24 mutations.
Pathogenicity of splice site mutations
Five ZMPSTE24 mutations collected in this study represent splice site
mutations (Table 2). Unfortunately, no biological material was
available for additional RT-PCR studies. However, all of them affect
the nucleotides of the canonical positions (2, 1, þ 1 or þ 2) and
therefore strongly influence the consensus value (CV). The CV was
calculated with three different prediction tools and all of them predict
a complete loss or a reduction about 30% of the initial CV
(Table 2).35 Thus, CVs smaller than 70% are associated with
potentially non-functional splice sites. For the c.1204-1G4A
mutation, two of three tools predicted a newly generated splice site
leading to a frame-shift of one base, which results in a predicted
premature stop codon (Table 2). For the remaining four mutations no
cryptic or new splice sites are predicted, most likely leading to exon
skipping. Two of these mutations, c.628-2A4G and c.954þ 2 T4A
(Table 2), would cause a frame-shift. The predicted effect of the
mutations c.475-2A4G and c.627þ 1G4C is the complete in-frame
skipping of exon 5. If this protein was produced, deletion of amino
acids 159–209 would eliminate ZMPSTE24 transmembrane domains
4 and 5, likely modifying the protein folding (Figure 3). Moreover,
Sander et al16 published in 2008 a homozygous splice site mutation
located at the donor splice site of intron 6 (c.627 þ 1G4C), which
induced skipping of the complete exon 5. The authors proved the
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exclusive expression of the shorter transcript carrying an in-frame
deletion and concluded that this transcript probably encoded a less
stable or less active protein, as demonstrated by prelamin A
accumulation.
We previously showed for the r.271_627del mutation the appear-
ance of a shorter in-frame transcript skipping exons 3–5, whose
corresponding protein was undetectable by western blot analyses.3 All
these arguments suggest that mutations affecting ZMPSTE24 splice
RD
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MAD / 
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one null allele associated with one 
haploinsufficient
Pro248Leu
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Figure 3 Examples of predicted mutant ZMPSTE24 forms. Left panel—null mutations observed in RD patients; Right panel—missense mutations involved
in milder progeroid syndromes. Antibody recognition site is indicated in red, endoplasmic reticulum retention signal is detailed in purple and catalytic site
in blue characters. Protein sequences modified by frame-shift mutations are indicated in green.
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sites may result in null mutations even when they predict transcript
in-frame deletions, at least as far as the region surrounding exon 5 is
affected.
Genotype–phenotype correlation
All the ZMPSTE24 mutations described in patients affected with RD
or MAD-B were homozygous or compound heterozygous. Based on
the recessive inheritance of the disease, heterozygous mutations
identified in healthy RD parents are apparently not deleterious. This
was also observed in Zmpste24þ / mice, which presented with
normal phenotypes, compared with Zmpste24/ mice, presenting
with progeroid features and shortened lifespans.31 It can thus be
postulated that one ZMPSTE24 wild-type allele is necessary and
sufficient for normal processing of prelamin A to mature lamin A,
and consequently compensate the null allele. Nonetheless, recently, a
heterozygous (c.1312C4T, p.Leu438Phe) mutation was identified in
a patient affected with a metabolic syndrome.36 In this patient, slight
prelamin A accumulation was detected by immunofluorescence
analyses in fibroblasts, associated with nuclear abnormalities. In this
case, processing of prelamin A was not complete as demonstrated by
ELISA. Furthermore, a reduced enzymatic activity for this variant was
confirmed by an in vitro essay.37 It is still not clear if this mutation is
acting per se or in combination with other unknown predisposing
factors. It would be interesting to clinically investigate the prevalence
of metabolic syndrome in heterozygous carriers of other ZMPSTE24
missense mutations. Indeed, to our knowledge, none of the RD
parents nor grandparents developed such a syndrome.
Disease-causing mutations have been observed throughout the
gene, as shown in Figure 4. However, a recurrent Thymine duplica-
tion (c.1085dupT) located in exon 9 has been frequently observed.
Considering all ZMPSTE24 mutations reported (Table 1), the
common thymine duplication occurs in 52.9%, of all progeroid
syndromes including RD, MAD and overlapping progeroid syn-
dromes, reported in the literature and in the present study
(Supplementary Table S3). Regarding mutation distribution classified
by phenotypes, this mutation represents 59.1% of all ZMPSTE24
mutations in association with the RD phenotype and 18.8% of the
MAD-B or overlapping syndromes HGPS/MAD.
Previously, 22 different mutations were reported in RD or other
severe progeroid syndromes, so that with the data included in this
report, 29 mutations have been described, to date. A total of 52 families
were linked to ZMPSTE24 mutations in the literature. Each of them
presented one or two affected children and 44 were associated with RD
phenotypes. Eight additional families with patients affected with MAD
or MAD/HGPS overlapping phenotypes were also associated with
Figure 4 Distribution of pathogenic mutations and sequence variations in ZMPSTE24. Exons are shown as gray rectangles. A red arrow indicates the ATG
start and adenine is numbered as nucleotide 1. Frame-shift mutations are shown in green, missense mutations leading to amino-acid changes in purple and
nonsense mutation in blue. One large genomic deletion is shown in orange and mutations affecting consensus splice sites are shown in red. Novel
mutations are indicated by (#); (~) indicates new sequence variations identified during our screening.
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mutations in this gene. Thus, all disorders associated with ZMPSTE24
mutations can be classified as secondary progeroid laminopathies.
Interestingly, except for the mutation c.1385C4T (p.Leu462Arg)
described by Thill et al17 and discussed below; all mutations involved
in RD are null mutations. The recurrent c.1085dupT results in the
complete absence of ZMPSTE24 in all patients tested, as shown by
western blot analysis.3 Moreover, no maturation of the yeast a-factor
was detected by enzymatic tests.13 Other null mutations are nonsense
mutations or frame-shifting splice site mutations leading to
premature stop codons. However, some null mutations could be
exon skipping mutations regarding the mRNA’s open reading frame
but resulting in degraded or inactive proteins. In contrast, all patients
with ‘non-RD’ progeroid syndromes are compound heterozygotes
carrying one null mutation and one missense mutation. Missense
mutations such as p.Trp340Arg or p.Asn265Ser lead to a reduced
catalytic ZMPSTE24 activity.13,27 All the reported cases of MAD-B
phenotypes followed this pathophysiological rule.22,23,25,27 An
apparent exception to this general rule has been reported by
Denecke et al26 but is explained by a digenic mechanism involving
both ZMPSTE24 and LMNA. The case reported in this study was
described as a HGPS patient but, according to molecular findings and
our current knowledge, it should be classified as a severe MAD-B. The
patient carried a homozygous ZMPSTE24 frame-shift mutation
(p.Val402Serfs*2) associated with a LMNA nonsense mutation
(p.Arg654*) acting as a salvage alteration alleviating the clinical
picture from RD to HGPS-like.26 Thill et al17 presented an exception
to the rule. They described a typical RD phenotype in a patient
carrying only a heterozygous missense mutation (p.Leu462Arg). The
authors discussed the fact that they could have missed a second
mutation, most probably because it was not detectable by conventional
PCR-based mutational analysis, limited to coding regions (excluding
heterozygous deletions, or pathogenic point mutations localized in
introns, promoters or UTR regions). However, all missense mutations
reported in ZMPSTE24 so far, except the latter, were associated with
less severe phenotypes than typical RD, with residual ZMPSTE24
catalytic activity. The authors argued that mutations involved in less
severe phenotypes are not located that close to the RE retention signal.
No tissues from the aborted fetus were available for western blot
analysis to validate the complete accumulation of prelamin A that is
always associated with a RD phenotype. Barrowman et al37 published a
proteolytic activity test concerning a wide list of ZMPSTE24 variants,
unfortunately Leu462Arg was not included in that study but this could
be an elegant way to demonstrate clearly a suggested null effect of this
mutation.
The major pathophysiological mechanism of RD is the dramatic
accumulation of prelamin A in its farnesylated form, because of the
complete absence of ZMPSTE24’s processing activity. Instead, a
residual enzymatic activity, with partial lamin A maturation, allows
longer life span. This was observed in MAD or ‘HGPS’ patients
carrying compound heterozygous loss-of-function and null
ZMPSTE24 mutations and recently confirmed with in vitro studies
in which enzymatic analyses performed on a series of ZMPSTE24
variants showed that residual proteolytic activity can be correlated
with disease severity.37 A patient carrying a homozygous loss-of-
function ZMPSTE24 mutation (c.281C4T, Leu94Pro) belongs to the
clinical continuum of this phenotypic group, as the milder phenotype
associated with ZMSPTE24 mutations, which correlated to slight
prelamin A accumulation.24
Finally, progeroid disorders caused by ZMPSTE24 recessive muta-
tions are always severe disorders. They are included in the nosologic
spectrum of lamin-associated progeroid syndromes, sharing a
common pathophysiologic pathway and being observed in MAD,
HGPS or RD patients. Each of these diseases can be caused either by
LMNA or ZMPSTE24 mutations; indeed, despite some clinical
differences, abnormal prelamin A processing and accumulation is a
common and central point of their pathophysiology. Nonetheless,
HGPS patients carrying ZMPSTE24 mutations, are not affected by the
‘classic’ form of HGPS, defined by the heterozygous recurrent LMNA
mutation (p.Gly608Gly) as well as by specific and highly reproducible
clinical and developmental features. Both the farnesylated state of the
precursor and its levels seem to be crucial points. Several studies
clearly demonstrated that the levels of accumulated prelamin A are
related to the severity of the phenotype. Indeed, double knock out
Zmpste24/ Lmnaþ / mice were phenotypically entirely normal,
lacking all disease features, compared with Zmpste24 / mice.38,39
Finally, Moulson et al34 and Reunert et al40 found larger amounts of
progerin in neonatal forms of progeria compared with several classic
ones and, conversely, lower progerin accumulation was observed in
mild progeria/atypical Werner syndromes.41
RD samples are extremely rare, moreover primary RD fibroblasts
are not easy to maintain in culture, because of their intrinsic
pathology. Consequently, the only available material is DNA in most
cases. In this context, in silico analyses concerning both RNA and
protein impacts of novel mutations are very useful. For this purpose,
electronic tools like HSF, BDGP and NetGene2 can help to predict
mutation impacts on the splicing machinery. The use of more than
one of such prediction tools is recommended as they use different
calculation algorithms, making common predictions more reliable
(Table 2). However, only functional expression analysis at the RNA
level on patients’ cells can validate the predictions. In addition, several
protein prediction programs can be used to explore the hypothetical
structure of a mutant in order to gain insight into the pathophysio-
logical mechanisms. As an example, c.1085dupT in ZMPSTE24 was
predicted to produce a mutant protein lacking the last transmem-
brane domain and the ER retention signal. In contrast, we detected
ZMPSTE24 mRNA by full length RT-PCR in patient 4 from our
previous studies1,3 carrying both c.1085dupT and r.271_627del
mutations, but no ZMPSTE24 protein was found by western blot
analyses. In this patient, ZMPSTE24 proteins lacking the ER retention
signal and/or one or several transmembrane domains may be
identified as misfolded proteins, being degraded by the proteaseome
(Figure 3). In patients carrying ZMPSTE24 mutations for whom no
RNA or proteins were available, bioinformatic tools can help to
predict the enzyme’s localization, conformation and consequently its
activity or fate. Very recently, two ZMPSTE24 structural studies
proved that mutations predicted to reduce ZMPSTE24 activity were
mapped in an unexpected voluminous peptide-binding chamber.
These new structural data will be helpful to predict pathogenicity of
novel missense mutations in this gene.42,43
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